New drug cocktail shows promise for rare, aggressive cancer
NCT ID NCT07510594
First seen Apr 13, 2026 · Last updated Jun 17, 2026 · Updated 13 times
Summary
This study tests a new combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare and fast-growing type of cancer called large-cell neuroendocrine carcinoma, which can start in the lung or elsewhere in the body. The goal is to see how many patients' tumors shrink or disappear. About 48 adults who have not had prior treatment for advanced disease will take part. This is an early-phase trial, so the main focus is on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.